Studies gauge value of chemotherapy on bladder and colon cancer patients
Queen's researcher conducts groundbreaking study of chemotheraphy therapy in colon and bladder cancer patients
Dr. Christopher Booth, Artsci’97, Meds’01, is interested in the societal benefit of cancer therapies beyond the findings of clinical trials.
A Cancer Care Ontario Chair in Health Services Research, he is an Assistant Professor with the Queen’s Cancer Research Institute, and an oncologist at the Cancer Centre of Southeastern Ontario. His research focuses on evaluating how new cancer treatments are being used in the general population in Ontario.
Booth’s clinical practice focuses on the treatment of patients with gastrointestinal and genitourinary cancers. He is currently conducting large studies to investigate the use of chemotherapy for bladder cancer and colon cancer, to better understand whether chemotherapy improves the long-term survival of patients with these diseases.
Booth is also investigating the role of exercise in colon cancer. “We're conducting a large clinical trial across Canada and Australia to evaluate whether exercise can improve the survival of patients with colon cancer. This study is first clinical trial in the world to test whether physical activity improves cancer survival,” he says.
Booth's enthusiasm for his research program, his teaching, and his clinical practice are clearly evident. “We're fortunate here at Queen’s to have a cluster of outstanding faculty in the field of cancer care and research," he says. "As I develop my academic career I've benefited tremendously from the mentorship of international leaders in this field who work right here at Queen’s.”
For more information, please visit http://chspr.queensu.ca/bio.php?User_ID=58